|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02096 SIMCERE PHARMA
Nominal 
13.460 0.000 (0.000%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 3,584,912 | 15.140% | 6,635,211 | 6,607,805 | 6,324,082 | 4,999,718 |
| Cost of Sales | (691,062) | 6.057% | (1,310,632) | (1,623,652) | (1,327,404) | (1,079,983) |
| Gross Profit | 2,893,850 | 17.544% | 5,324,579 | 4,984,153 | 4,996,678 | 3,919,735 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (173) | -- | 2,162 | 7,844 | 190 | (44,186) | |
| Profit / (Loss) before Taxation | 662,485 | 33.918% | 819,878 | 740,038 | 886,254 | 1,401,797 | |
| Taxation | (58,878) | 54.564% | (86,713) | (26,088) | 40,478 | 97,124 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 811 | 4,136 | 8,175 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 603,607 | 32.196% | 733,165 | 714,761 | 930,868 | 1,507,096 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 21,988 | -- | 30,331 | (20,392) | (25,459) | 2,561 |
| Depreciation & Amortisation | 175,924 | 9.102% | 337,647 | 309,594 | 283,647 | 251,807 |
| Directors' Emoluments | -- | -- | 67,540 | 34,084 | 35,451 | 21,726 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 25.000 | 38.889% | 29.000 | 27.000 | 36.000 | 58.000 |
| DPS (cts) | 0.000 | -- | 16.000 | 16.000 | 16.000 | 15.000 |
| Dividend Payout Ratio (%) | -- | -- | 55.172% | 59.259% | 44.444% | 25.862% |
| Cash flow per share ($) | -- | -- | 0.554 | 0.058 | 0.519 | (0.077) |
| NBV per share ($) | 2.923 | -- | 2.797 | 2.745 | 2.681 | 2.449 |
| Remarks: | Real time quote last updated: 12/09/2025 08:26 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 603,607 |
| %Change | 32.196% |
| EPS / (LPS) | RMB 0.250 |
| NBV Per Share (¥) | RMB 2.923 |